MicroRNA-7: a promising new target in cancer therapy

Juanjuan Zhao¹, Yijing Tao¹, Ya Zhou², Nalin Qin¹, Chao Chen¹, Dan Tian¹ and Lin Xu¹*

Abstract
The incidence of tumors with life-threatening effects has increased gradually over time; however, the mechanisms involved in tumor development have not been fully elucidated. Recent studies have shown that microRNA-7 (miR-7), which is endogenous non-coding RNA molecules of approximately 23 nucleotides, plays an important role in the occurrence and development of tumors as a key tumor suppressor. Mechanistic evidence showed that miR-7 is closely related to the growth, metastasis, and prognosis of various malignant tumors through regulating different target molecules, which suggest that miR-7 may be a new target for the clinical diagnosis and treatment of various tumors. In this review, we summarize current knowledge of the relationship between miR-7 and tumor development, diagnosis, and treatment.

Keywords: Tumors, MiR-7, Diagnosis, Treatment

Background
MicroRNAs (miRNAs) are small noncoding RNAs that posttranscriptionally regulating target gene expression through base pairing to partially complementary sites to prevent protein accumulation by repressing translation or by inducing mRNA degradation [1, 2]. The primary transcripts of miRNA (pri-miRNA) are cleaved into precursor miRNA (pre-miRNA) by nuclear RNase III Drosha, and further processed to mature miRNAs by cytoplasmic RNase III Dicer [3, 4]. Up to data, the involvement of miRNAs in human cancer has led to extensive research [5–7]. More and more evidences showed that miRNAs were not only dysregulated in almost all types of cancers but also were potential specific signatures for the characterization of poorly differentiated tumors, which might harbor relevant clinical implications. Further studies suggested that miRNAs in cancers could be divided into two types including oncogenic miRNAs (Oncomirs) and tumor suppressor miRNAs. Oncomirs are reported upregulated in cancer cells and contributed to carcinogenesis by inhibiting tumor suppressor genes. Conversely, tumor suppressor miRNAs are documented could prevent cancer development by inhibiting the expression of oncogenes. Experimental data in some animal tumor models showed that silencing oncomirs with miRNA inhibitors or replacing tumor suppressor miRNAs with synthetic miRNA mimics may be valuable strategy for the treatment of solid and hematological malignancies, which suggesting a particularly promising in translational therapy against tumors.

MicroRNA-7 (miR-7) was first identified by Lagos-Quintana in 2001 [8]. In humans, miR-7 is encoded by three different genomic loci 9q21, 15q26, 19q13 respectively. The products of three different DNA sequences (termed as pri-miR-7-1, pri-miR-7-2, and pri-miR-7-3) can be processed into the same mature miR-7 sequence which comprising 23 nucleotides [9]. The mature miR-7 is then incorporated into a RNA-induced silencing complex (RISC), which recognizes target miRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA (Fig. 1). Many studies have reported that miR-7 is enriched in a variety of normal tissues and involved in both the development of multiple organs and biological functions of cells [10, 11]. Moreover, some tissues related factors could regulate the expression of miR-7; for example, transcription factor NeuroD/Beta2...
Fig. 1 Structure of the human miR-7 hairpin precursors and mature sequences. MiR-7 is transcribed from three different genomic loci on chromosomes 9, 15, 19 into primary miR-7 transcripts (pri-miR-7-1, pre-miR-7-2, pri-miR-7-3 respectively), which are processed into hairpin precursor molecules (pre-miR-7-1, pre-miR-7-2, pre-miR-7-3), and then further into the same mature miR-7 sequences, which are incorporated into the RISC complex and guided to miR-7 target mRNAs to repress their expression.
P21-activated kinase 1 (PAK1) is expressed at high levels in breast cancer cell growth, metastasis, and invasion. It can negatively regulate a variety of molecules involved in the cell cycle progression of breast cancer cells, which closely related to metastasis of cancer cells [18]. A study of breast cancer tissue specimens revealed a positive correlation between the expression levels of miR-7 and E-cadherin, and a negative correlation between the expression levels of miR-7 and Vimentin [19], indicating miR-7 might be involved in the metastasis of breast cancer. Importantly, the expression level of miR-7 in metastatic breast cancer tissues was significantly lower than that in normal breast tissues. Furthermore, an increase in the expression level of miR-7 could dramatically inhibit the growth and invasiveness of breast cancer cells in animal models, indicating that miR-7 plays an important role in metastasis of breast cancer [19].

Successive studies have demonstrated that miR-7 can negatively regulate a variety of molecules involved in breast cancer cell growth, metastasis, and invasion. P21-activated kinase 1 (PAK1) is expressed at high levels in many human cancer tissues and is closely related to mitosis of tumor cells, regeneration of the cytoskeleton structure, cell migration and apoptosis [20]. Reddy et al. showed that miR-7 binds to a complementary site in the 3′ untranslated region (UTR) of the mRNA encoding SET domain-containing lysine (lysine methyltransferase) 8 (SET8), which closely related to metastasis of cancer cells [18]. A study of breast cancer tissue specimens revealed a positive correlation between the expression levels of miR-7 and E-cadherin, and a negative correlation between the expression levels of miR-7 and Vimentin [19], indicating miR-7 might be involved in the metastasis of breast cancer. Importantly, the expression level of miR-7 in metastatic breast cancer tissues was significantly lower than that in normal breast tissues. Furthermore, an increase in the expression level of miR-7 could dramatically inhibit the growth and invasiveness of breast cancer cells in animal models, indicating that miR-7 plays an important role in metastasis of breast cancer [19].

The underlying mechanism through which miR-7 regulates breast cancer cell growth and metastasis is complex, it does not involve only the above mentioned molecular targets and signal transmission pathways but also some transcription factors and DNA damage repair processes. For example, Li et al. demonstrated that miR-7 can reactivate the Ras association domain family 1A (Raf1A) and tumor suppressors claudin-6 by targeting the gene encoding homeobox B3 (HoxB3), therefore inhibit the growth and colony formation capacity of breast cancer cells [25]. In addition, Yu et al. showed that miR-7 binds to the 3′UTR of the mRNA encoding SET domain-containing lysine (lysine methyltransferase) 8 (SET8) to downregulate its expression in breast cancer cells [26]. In higher eukaryotes, SET8 is involved in gene transcription and the cell cycle progression of breast cancer cells, and is also related to a variety of biological processes, including DNA damage and repair [27]. Moreover, MiR-7 can reduce the monomethylation of histone H4 lysine 20 by targeting SET8, then inhibiting the occurrence, development, and invasion of breast cancer [26]. In addition, some studies reported that miR-7 accelerates spontaneous DNA damage and sensitizes breast cancer cells to this type of damage. Taken together, these findings indicate that miR-7 can regulate the development and progression of breast cancer through multiple targets or pathways; hence, miR-7 based breast cancer gene therapy is expected to become an important area of related research.

The current understanding of the mechanism of regulating miR-7 expression in breast cancer cells still is limited. MiR-7 expression is upregulated by the transcription factor HoxD10. When the level of HoxD10 is decreased, the expression level of miR-7 is also decreased. Successively, the expression level of its target molecule PAK1 is increased significantly, the growth and invasiveness of breast cancer cells is enhanced [21]. Due to the complexity of the mechanisms of regulation of miRNAs, additional analyses on off factors that affect miR-7 expression in breast cancer are required.

**MiR-7 and lung cancer**

MiR-7 plays an important role in suppressing the migration, colony formation, and cell-cycle progression of lung cancer cells. Reducing the amount of miR-7 can promote the growth and metastasis of human lung carcinoma A549 and H1299 cells significantly [28]. Furthermore, increasing the level of miR-7 can reduce the levels of cell-cycle-associated proteins and inhibit the proliferation of human lung cancer cells, suggesting that miR-7 is closely related to development of lung cancer. It is well known that epidermal growth factor receptor (EGFR) is critical factor for the growth and metastasis of human...
lung cancer cells [29, 30]. Mechanistic evidence showed that miR-7 can inhibit the proliferation of lung cancer cells through regulating the expression of EGFR by binding to the 3′UTR region of EGFR mRNA [28]. In addition, Xiong et al. showed that miR-7 downregulated the expression of the gene encoding BCL-2, thereby inhibiting the proliferation and promoting the apoptosis of lung adenocarcinoma A549 cells [31]. Other studies also reported that miR-7 targets and downregulates proteasome activator 28 subunit γ, which contributes to the carcinogenesis of non-small cell lung cancer, and inhibits apoptosis and accelerates the cell cycle in lung cancer cells [32]. Moreover, Zhou et al. showed that the regulatory effect of miR-7 on the growth of human lung cancer cells may be associated with the downregulated expression of Solute Carrier Family 7 (Amino Acid Transporter Light Chain, L System), Member 5 (SLC7A5), which was a member of the L-type amino acid transporter (LAT) family and was involved in the growth of cancer cells [33–35]. In contrast to these literatures, other studies showed that inhibition of miR-7 could reduce the growth of lung cancer cell line A549 cells [36]. Based on these contradictory data, we propose that this might reflect the fact that miR-7 plays a crucial role in lung cancer cell growth, invasion, and metastasis, although the mechanisms involved in regulating these processes may be complex, which was closely related to the cellular context, growth conditions and specific targeted genes.

A number of studies have shown that miR-7 also is involved in the signal transduction and regulatory processes of other membrane-bound proteins in lung cancer cells, such as the pattern-recognition molecules Toll-like receptor 9 (TLR9). Our recent study showed that miR-7 may negatively regulate the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway by acting on PI3K regulatory subunit 3, thereby blocking the TLR9 signal transduction process and inhibiting cancer cell growth and metastasis [37]. Furthermore, activation of TLR9 signaling can inhibit the cleavage of the endogenous miR-7 precursor in lung cancer cells by inducing the expression of human antigen R (HuR), therefore reduce the level of mature miR-7 and accelerate the growth and metastatic progression of the cells [38].

The treatment of lung cancer could lead to an acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). However, in about 50% of patients with TKIs resistance, this resistance is caused by a T790M mutation in exon 20 of the EGFR gene [39]. Interestingly, Rai et al. showed that expression of exogenous miR-7 in nude mice bearing RPC-9 and H1975 lung cancer cells, which have a high tolerance to TKIs, inhibited the growth of tumors, suggesting that miR-7, as a tumor suppressor miRNA, may be an important target for lung cancer gene therapy [40].

**MiR-7 and brain cancer**

MiR-7 is enriched in the brain and regulates neuronal differentiation, maturation, and survival [41]. There is increasing evidence that miR-7 is a robust suppressor of the growth, metastasis, and invasion of glioblastoma; for example, Liu et al. showed that miR-7 can suppress glioblastomagenesis by regulating the PI3K/AKT and Raf/mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) pathways, which are downstream signaling pathways of the EGFR [42]. Furthermore, miR-7 may regulate brain tumorigenesis by targeting oncogenic proteins and critical factors such as c-KIT, Y box binding protein 1, AKT2, cell division control protein 42, cyclin-dependent kinase 6, and transforming growth factor β2 (TGF-β2), which can also affect the expression of miR-7 in a feedback loop [43]. Similar to the anti-angiogenic drug sunitinib, miR-7 can reduce vascularization in the chick chorioallantoic membrane assay. Furthermore, local application of miR-7 to neuroblastoma model mice harboring human glioblastoma xenografts reduces angiogenesis and tumor cell proliferation by targeting the 3′UTR of the FAK mRNA [44]. In addition, miR-7 also can inhibit glioblastoma cell invasion by downregulating the expression levels of p-ERK1/2, p-AKT, Raf-1, and cyclin D1 [42]. There also are some reports suggesting that brain-enriched ciRS-7, a circular RNA containing 70 conserved miR-7 target sites, can downregulate the expression of miR-7 and promote the development of neuroblastomas and astrocytomas [45]. Conversely, miR-671 can release the expression of miR-7 by binding to ciRS-7 [46]. Overall, these findings suggest that miR-7 may be a potential therapeutic target to suppress brain tumorigenesis, metastasis, and invasion.

**MiR-7 and other tumors**

Recently, a large number of studies have demonstrated that miR-7 is related to liver cancer [47], colorectal cancer [48], gastric tumor [49], and ovarian cancer [50]. Using immunohistochemistry, real-time PCR, and luciferase reporter genes assay, Needhamsen et al. showed that the human gene encoding paired box 6 (PAX6) is an putative target of miR-7 [51]. PAX6 is a highly conserved transcription factor that is expressed in colorectal cancer cells and plays an important regulatory role in the development of colorectal cancer [52]. Overexpression of PAX6 in human colonic adenocarcinoma SW480 cells activates the ERK/PI3K signaling pathway and upregulates the expression levels of MMP2 and MMP9, resulting in the enhancement of cancer cell growth, proliferation, and metastatic capacity. By contrast, miR-7 reduces PAX6 expression in colorectal cancer cell lines and inhibits the corresponding signaling through the ERK/PI3K pathway, resulting in downregulated growth,
proliferation, and metastasis of these cells significantly [53]. Meanwhile, in vivo experiments revealed that miR-7 could bind to the 3’ UTR of the mRNA encoding Yin Yang 1, which was a multifunctional transcription factor and was reported contributed to growth of cancer cells, and inhibit its expression, thereby attenuated colorectal cancer cell growth and invasion [54].

Fang et al. showed that miR-7 arrests hepatocellular carcinoma cells in the G0/G1 phase and negatively regulates the PI3K/AKT pathway by targeting AKT, mammalian target of rapamycin, and ribosomal protein S6 kinase, which are key signaling molecules involved in the promotion of liver cancer cell growth and metastasis [55]. MiR-7 may also play an important role in discriminating between benign and malignant cells in B-chronic lymphocytic leukemia [56]. In addition, Zhao et al. showed that miR-7 binds to the 3’ UTR of the mRNA encoding insulin-like growth factor 1 receptor and induces cadherin expression and reversal of the epithelial-mesenchymal transition of gastric cancer cells, successively inhibited gastric cancer metastasis [57]. A number of other types of cancer are also reported closely related to miR-7 (summarized in Table 1), suggesting that this miRNA may be a novel clinical target for the treatment of a variety of tumors.

### Table 1 The targets of miR-7 in different tumor types

| Tumor type                     | Target site(s)          | Reference(s) | Role of target site |
|--------------------------------|-------------------------|--------------|---------------------|
| Breast cancer                  | FAK, PAK1, EGFR, KLF4, HoxB3, SET8 | [19, 21, 22, 24–26] | Suppressor          |
| Lung cancer                    | PA2B2y, BCL-2, EGFR, SLC7A5, HuR | [32, 35, 38 39] | Suppressor          |
| Hepatocellular carcinoma       | CCNE1, PI3KCD, mTOR, p70S6K, GSK-3B | [48, 54] | Suppressor          |
| Glioma                         | EGFR, C-KIT, FAK, ERK, ciRS-7 | [42–44, 46] | Suppressor          |
| Colorectal cancer              | XRCC2, PAX6, YY1         | [49, 52, 53] | Suppressor          |
| Gastric cancer                 | EGFR, IGFR1             | [42, 56] | Suppressor          |
| Acute myelocytic leukemia      | TET2                    | [58] | Suppressor          |
| Urothelium carcinoma           | FGFR3                   | [59] | Suppressor          |
| Cervical cancer                | XIAP                    | [60] | Suppressor          |
| Renal carcinoma                | None reported           | [61] | Oncogene           |
| Melanoma                       | IRS-2                   | [62] | Suppressor          |
| Ovarian cancer                 | EGFR, ERK               | [50] | Suppressor          |
| Oral cancer                    | RECK                    | [63] | Oncogene           |
| Neuroblastoma                  | 4-HPR, EGCG             | [64] | Suppressor          |
| Pancreatic carcinoma           | MAPK                    | [65] | suppressor         |
| Pleural mesothelioma           | None reported           | [66] | Suppressor          |
| Schwannoma tumors              | EGFR, ACK1, PAK1        | [67] | Suppressor          |
| Tongue squamous carcinoma      | IGFR1                   | [68] | Suppressor          |

**FAK** focal adhesion kinase, **PAK1** p21 activated kinase 1, **EGFR** epidermal growth factor receptor, **KLF4** Krüppel-like factor 4, **HoxB3** homeobox B3, **SET8** SET-domain-containing (lysine methyltransferase) 8, **PA2B2y** proteasome activator 28 subunit y, **HuR** human antigen R, **PI3KCD** phosphoinositide 3-kinase catalytic subunit delta, **mTOR** mammalian target of rapamycin, **p70S6K** ribosomal protein S6 kinase, **GSK-3β** glycogen synthase kinase 3, **ciRS-7** circular RNA sponge for miR-7, **XRCC2** X-ray repair complementing defective repair in Chinese hamster cells 2, **PAX6** paired box 6, **YY1** Yin Yang 1, **IGF1R** insulin-like growth factor 1 receptor, **TET2** tet methylcytosine dioxygenase 2, **FGFR3** fibroblast growth factor receptor 3, **MAPK** mitogen-activated protein kinase, **ACK1** associated cdc42 kinase 1

**MiR-7 and tumor diagnosis, therapy**

Multiple studies have suggested that miR-7 can be used as a potential diagnostic marker of cancer. For example, the expression level of miR-7 is significantly lower in lung cancer tissues than normal lung tissues, and downregulation of miR-7 expression is associated with lung cancer metastasis [32]. Kitano et al. showed that miR-7 expression level predicts thyroid cancer prognosis with an accuracy of approximately 76% [69]. Other groups used non-invasive detection methods and found that the serum level of miR-7 is significantly lower in patients with colorectal cancer than healthy controls [70]. Moreover, fecal expression levels of miR-7 was remarkable difference between colorectal cancer patients and healthy controls, suggesting that non-invasive detection of miR-7 can be used for the auxiliary diagnosis of colorectal cancer [71]. In addition, other studies have suggested that miR-7 may be an important clinical predictor of recurrence. For example, Duncavage et al. showed that the expression level of miR-7 in relapsed lung cancer patients is significantly lower than that in healthy individuals, suggesting a relationship between reduced expression of miR-7 and lung cancer recurrence [72].

To the therapy against cancer, the related progression still is limited but promising. Overexpression of
miR-7 using a eukaryotic expression vector can inhibit the growth of TKI-resistant lung cancer cell significantly in vivo. Tazawa et al. constructed an oncolytic adenovirus that upregulated miR-7 expression and induced apoptosis of human tumor cells through the activation of the transcription factor E2F1/miR-7/EGFR pathway, suggesting a potential new method of inducing tumor cell death by controlling miR-7 levels [73]. In addition, Lee et al. reported that overexpression of miR-7 increases the radiosensitivity of cancer cells, suggesting that this miRNA may have a positive effect on radiation therapy of tumors [74]; however, further analyses are required to clarify the relationship between tumor diagnosis/treatment and the expression levels of miR-7 in different tissues and organs. In all, the development of miR-7-based therapeutic strategy, including the application of efficient synthetic systems for miR-7 delivery, remains to be fully investigated in future.

**Conclusion**

In this review, we have tried to discuss miR-7 as a promising target in cancers. Although substantial progress has been made in the mechanisms by which miR-7 controls tumor cell growth, proliferation, invasion, and metastasis, however, a number of issues require further investigation, such as the precise regulatory mechanisms of miR-7, the relationships between its target genes, and the ways in which targeting miR-7 can be used to develop agents that have desirable effects on distinct types of cancers, which will provide robust and valuable information related to the clinical diagnosis, treatment, and prognoses of various cancers.

**Authors’ contributions**

All of authors carried out reading the related literatures and drafting the manuscript. Xu designed the outline of manuscript. All authors read and approved the final manuscript.

**Author details**

1. Department of Medical Physics, Zunyi Medical College, Guizhou 563000, People’s Republic of China. 2. Department of Immunology, Zunyi Medical College, Guizhou 563000, China.

**Acknowledgements**

This review manuscript was supported by Program for New Century Excellent Talents in University, Ministry of Education of China (NCET-12-0661), National Natural Science foundation of China (31370918, 81260398), International Cooperation Foundation of Guizhou Province (2010-7031), Specific Foundation for the Scientific Educational Talent of President of Guizhou Province (09CQ57), Project of Guizhou Provincial Department of Science and Technology (2009C491) and Zunyi Medical College Start-up Fund (2008F-329).

**Competing interests**

The authors declare that they have no competing interests.

**Received** 22 September 2015  **Accepted** 20 October 2015  **Published online** 29 October 2015

**References**

1. Li X, Yang W, Lou L, Chen Y, Wu S, Ding G. microRNA: a promising diagnostic biomarker and therapeutic target for hepatocellular carcinoma. Dig Dis Sci. 2014;59(6):1099–107.

2. Pichler M, Calin GA. MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients. Br J Cancer. 2015;113(4):569–73.

3. Burger K, Gullerova M. Swiss army knives: non-canonical functions of nuclear Drosha and Dicer. Nat Rev Mol Cell Biol. 2015;16(7):417–30.

4. Akahane T. Clinicopathological and prognostic significance of the microRNA processing enzyme Dicer1: mRNA expression in colorectal cancer patients. Mol Clin Oncol. 2013;1(2):267–73.

5. Ren F, Ding H, Huang S, Wang H, Wu M, Luo D, Dang Y, Yang L, et al. Expression and clinicopathological significance of miR-193a-3p and its potential target astrocyte elevated gene-1 in non-small lung cancer tissues. Cancer Cell Int. 2015;15:80.

6. Kato H. Cardio-miRNAs and onco-miRNAs: circulating miRNA-based diagnostics for non-cancerous and cancerous diseases. Front Cell Dev Biol. 2014;2:61.

7. Tao Y, Li Y, Zheng W, Zhao J, Guo M, Yu Zhou, et al. Antisense oligonucleotides against microRNA-21 reduced the proliferation and migration of human colon carcinoma cells. Cancer Cell Int. 2015;15:77.

8. Lagos-Quintana M, Rieuft R, Lendeckel W, Tuschi T. Identification of novel genes coding for small expressed RNAs. Science. 2001;294(5543):853–8.

9. Kalinowski FC, Brown RA, Garda C, Giles KM, Epsis MR, Horsham JM, et al. microRNA-7: a tumor suppressor miRNA with therapeutic potential. Int J Biochem Cell Biol. 2014;54:312–7.

10. Yan B, Wang ZH, Zhu CD, Guo JT, Zhao JL. MicroRNA repertoire for functional genomic research in tilapia identified by deep sequencing. Mol Biol Rep. 2014;41(8):14953–63.

11. Kredo-Russo S, Mandelbaum AD, Ness A, Alon I, Lennon KA, Behlke MA, et al. Pancreas-enriched miRNA refines endocrine cell differentiation. Development. 2012;139(16):3021–31.

12. Kredo-Russo S, Ness A, Mandelbaum AD, Walker MD, Horstein E. Regulation of pancreatic microRNA-7 expression. Exp Diabetes Res. 2012;2012:695214.

13. Choudhury NR, de Lima Alves F, de Andrés-Aguayo L, Graff T, Cáceres JF, Rappsilber J, et al. Tissue-specific control of brain-enriched miR-7 biogenesis. Genes Dev. 2013;27(1):24–38.

14. Marzioni M, Agostinelli L, Candelaresi C, Saccomanno S, De Minicis S, Maroni L, et al. Activation of the developmental pathway neurogenin-3/microRNA-7a regulates cholangiocyte proliferation in response to injury. Hepatology. 2014;60(4):1324–35.

15. Ma J, Fang B, Zeng F, Pang H, Zhang J, Shi Y, et al. Curcumin inhibits cell growth and invasion through up-regulation of miR-7 in pancreatic cancer cells. Toxicol Lett. 2014;231(1):82–91.

16. Meza-SosaKF, Pérez-Garcia EI, Camache-Concha N, López-Gutierrez O, Pedraza-Alva G, Pérez-Martinez L. MiR-7 promotes epithelial cell transformation by targeting the tumor suppressor KLF4. PLoS One. 2014;9(9):e103987.

17. Liu Z, Liu Y, Li L, Xu Z, Bi B, Wang Y, et al. MiR-7-5p is frequently downregulated in glioblastoma microvasculature and inhibits vascular endothelial cell proliferation by targeting RAI1. Tumour Biol. 2014;35(10):1077–84.

18. Díaz-López A, Moreno-Bueno G, Cano A. Role of microRNA in epithelial to mesenchymal transition and metastasis and clinical perspectives. Cancer Manag Res. 2014;6:205–16.

19. Kong X, Li G, Yuan Y, He Y, Wu X, Zhang W, et al. MicroRNA-7 inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via targeting FAK expression. PLoS One. 2012;7(8):e41523.

20. Radu M, Semenova G, Kosoff R, Chernoff J. PAK signalling during the development and progression of cancer. Nat Rev Cancer. 2014;14(1):13–25.

21. Reddy SD, Ohshiro K, Rayala SK, Kumar R. MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer Res. 2008;68(20):8195–200.

22. Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, Leedman PJ. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem. 2009;284(9):5731–41.
23. Jia J, Martin TA, Ye L, Jiang WG. FAP-a (Fibroblast activation protein-a) is involved in the control of human breast cancer cell line growth and motility via the FAK pathway. BMC Cell Biol. 2014;15:16.

24. Okuda H, Xing F, Pandey PR, Sharma S, Watabe M, Pai SK, et al. miR-7 suppresses brain metastasis of breast cancer stem-like cells by modulating KLK4. Cancer Res. 2013;73(4):1343–44.

25. Li Q, Zhu F, Chen P. miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB5 in breast cancer. Biochem Biophys Res Commun. 2012;424(1):28–33.

26. Yu N, Huangyang P, Yang X, Han Y, Yan R, Ji H, et al. miRNA-7 suppresses the invasive potential of breast cancer cells and sensitizes cells to DNA damages by targeting histone methyltransferase SET8. J Biol Chem. 2013;288(27):19633–42.

27. Dulev S, Tichak J, Lin S, Batada NN. SET8 methyltransferase activity during the DNA double-strand break response is required for recruitment of S3BP1. EMBO Rep. 2014;15(11):1163–74.

28. Chan LW, Wang PF, Cho WC. Genomic sequence analysis of EGFR regulation by microRNAs in lung cancer. Curr Top Med Chem. 2012;12(8):920–6.

29. Li J, Zheng Y, Sun G, Xiong S. Restoration of miR-7 expression suppresses the growth of Lewis lung cancer cells by modulating epidermal growth factor receptor signaling. Oncol Rep. 2014;32(6):2511–6.

30. Blumenberg M. Differential transcriptional effects of EGFR inhibitors. PLoS One. 2014;9(6):e96266.

31. Xiong S, Zheng Y, Jiang P, Liu R, Liu X, Chu Y. MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2. Int J Biol Sci. 2011;7(6):805–14.

32. Xiong S, Zheng Y, Jiang P, Liu R, Liu X, Qian J, et al. Proteasome activator PA28 gamma regulates p53 by enhancing its MDM2-mediated degradation. EMBO J. 2008;27(8):852–64.

33. Dann SG, Ryskin M, Barsotti AM, Golas J, Shi C, Miranda M, et al. Reciprocal regulation of amino acid import and epigenetic state through Lat1 and EZH2. EMBO J. 2015;34(13):1773–85.

34. Lindskog C, Edlund K, Mattsson JS, Mickie P. Immunohistochromatography-based prognostic biomarkers in NSCLC: novel findings on the road to clinical use? Expert Rev Mol Diagn. 2015;15(4):471–90.

35. Zhou C, Chen H, Han L, Wang A, Chen L.A. Identification of featured biomarkers in different types of lung cancer with DNA microarray. Mol Biol Rep. 2014;41(10):6357–63.

36. Cheng AM, Byrom MW, Shelton J, Ford LP. Antisense inhibition of human EZH2. EMBO J. 2000;19(6):1413–21.

37. Xu L, Wen Z, Zhou Y, Liu Z, Qiu F, et al. MicroRNA-7-regulated TLR9 expression. Chin Med J (Engl). 2011;124(17):2616–21.

38. Li YJ, Wang CH, Zhou Y, Liao ZY, Zhu SF, Hu Y, et al. TLR9 signaling inhibitor of YY1 contributing to colorectal tumorigenesis. Oncogene. 2013;32(42):5078–88.

39. Fang Y, Xue JL, Shen Q, Chen J, Tian L. MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide-3-kinase/Akt pathway in hepatocellular carcinoma. Hepatolology. 2012;55(6):1852–62.

40. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, et al. MicroRNA profiling reveals distinct signatures in 8 cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA. 2004;101(52):1755–60.

41. Zhao X, Dou W, He L, Liang S, Tie J, Liu C, et al. MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor. Oncogene. 2013;32(11):1363–72.

42. Cheng J, Guo S, Chen S, Mastrianos SJ, Liu C, D’Alessio AC, et al. An extensive network of TE2-targeting microRNAs regulates hepatopoeisis. Cell Rep. 2013;5(2):471–81.

43. Veerla S, Lindgren D, Kvist A, Friyesa A, Staaf J, Persson H, et al. MicroRNA expression in uveal melanomas: important roles of miR-130a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer. 2009;124(9):2236–42.

44. Liu S, Zhang P, Chen Z, Liu M, Li X, Tang H. MicroRNA-7 downregulates XIAP expression to suppress cell growth and promote apoptosis in cervical cancer cells. FEBS Lett. 2013;587(14):2247–53.

45. Xu K, Chen Z, Wang Y, Zeng Q, Su Z, Wang Y, et al. Identification of miR-7 as an oncogene in renal cell carcinoma. J Mol Histol. 2013;44(6):669–77.

46. Giles KM, Brown RA, Eipir MR, Kalinowski FC, Leedman PJ, miRNA-7-5p inhibits melanoma cell migration and invasion. Biochim Biophys Res Commun. 2013;430(2):706–10.

47. Jung HM, Phillips BL, Patel RS, Cohen DM, Jakymiw A, Konig M, et al. Keratinization-associated miR-7 and miR-21 regulate tumor suppressor reversion-inducing-cysteine-rich protein with kazal motifs (RECK) in oral cancer. J Biol Chem. 2012;287(35):29261–72.

48. Chakrabarti M, Khandkar M, Bank NL, Ray SK. Alterations in expression of specific microRNAs by combination of 4-HPR and EGCG inhibited growth of human malignant neuroblastoma cells. Brain Res. 2012;1454:1–13.

49. Ikeda Y, Tanji E, Makino N, Kawata S, Furukawa T. MicroRNAs associated with mitogen-activated protein kinase in human pancreatic cancer. Mol Cancer Res. 2012;10(2):259–69.

50. Balatti V, Maniero S, Ferracin M, Veronesi A, Negrini M, Ferracchiati G, et al. MicroRNAs dysregulation in human malignant pleural mesothelioma. J Thorac Oncol. 2011;6(5):844–51.

51. Saydam O, Senel D, Wurdinger T, Mitra A, Oedeker GN, Stemmer-Rachamimov AO, et al. miRNA-7 attenuation in Schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways. Cancer Res. 2011;71(3):852–61.
68. Jiang L, Liu X, Chen Z, Jin Y, Heidbreder CE, Kolokythas A, et al. MicroRNA-7 targets IGF1R (insulin-like growth factor 1 receptor) in tongue squamous cell carcinoma cells. Biochem J. 2010;432(1):199–205.

69. Kitano M, Rahbari R, Patterson EE, Steinberg SM, Prasad NB, Wang Y, et al. Evaluation of candidate diagnostic microRNAs in thyroid fine-needle aspiration biopsy samples. Thyroid. 2012;22(3):285–91.

70. Wang S, Xiang J, Li Z, Lu S, Hu J, Gao X, et al. A plasma microRNA panel for early detection of colorectal cancer. Int J Cancer. 2015;136(1):152–61.

71. Ahmed FE, Ahmed NC, Vos PW, Bonnerup C, Atkins JN, Casey M, et al. Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle. Cancer Genom Proteom. 2013;10(3):93–113.

72. Duncavage E, Goodgame B, Sezhiyan A, Govindan R, Pfeifer J. Use of microRNA expression levels to predict outcomes in resected stage I non-small cell lung cancer. J Thorac Oncol. 2010;5(11):1755–63.

73. Tazawa H, Yano S, Yoshida R, Yamasaki Y, Sasaki T, Hashimoto Y, et al. Genetically engineered oncolytic adenovirus induces autophagic cell death through an E2F1-microRNA-7-epidermal growth factor receptor axis. Int J Cancer. 2012;131(2):2939–50.

74. Lee KM, Choi EJ, Kim IA. microRNA-7 increases radiosensitivity of human cancer cells with activated EGFR-associated signaling. Radiother Oncol. 2011;101(1):171–6.